Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
Ponatinib has shown to induce deeper molecular responses compared with imatinib. Therefore,
ponatinib treatment could increase the proportion of patients who could discontinue treatment
successfully. This strategy that includes treatment change to a more powerful treatment
before treatment discontinuation has not been evaluated in any of the previous clinical
trials, and will be explored in the current study.
In this framework, the purpose is to determine the rate of successful treatment-free
remission (TFR) within the first 48 weeks following cessation of treatment in patients who
achieved Molecular Response 4 (MR4) on imatinib and maintained MR4 on ponatinib after a
switch from imatinib. Eligible patients have been previously treated with imatinib as unique
tyrosine kinase inhibitor (at least 4 years) and have documented MR4 (at least 12 months) at
the time of switch to ponatinib to study entry.